Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations

BACKGROUND: Options for opioid agonist therapy (OAT) are expanding with the development of prolonged-release (also known as extended-release) 1-week, 1-month, and 6-month formulations of buprenorphine. There is an assumption that patients will welcome these new treatments and medication adherence wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Neale, Joanne, Tompkins, Charlotte N. E., Strang, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446264/
https://www.ncbi.nlm.nih.gov/pubmed/30943990
http://dx.doi.org/10.1186/s12954-019-0296-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446264/
https://www.ncbi.nlm.nih.gov/pubmed/30943990
http://dx.doi.org/10.1186/s12954-019-0296-4

Ejemplares similares